Dasatinib for the treatment of chronic phase chronic myeloid leukemia

Author： Campbell Victoria   Copland Mhairi  

Publisher： Future Medicine

ISSN： 2044-9038

Source： Clinical Practice, Vol.10, Iss.4, 2013-07, pp. : 415-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dasatinib in the Treatment of Chronic Myeloid Leukemia

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia

By Yood Marianne Ulcickas   Oliveria Susan A.   Cziraky Mark   Hirji Ishan   Hamdan Muhammad   Davis Catherine  

Current Medical Research and Opinion, Vol. 28, Iss. 2, 2012-02 ,pp. : 213-219

Informa Healthcare

Access to resources Recommend Favorite

Diagnosis of Blastic Phase of Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 4, 2012-03 ,pp. : 198-198

Karger

Access to resources Recommend Favorite

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : 242-249

John Wiley & Sons Inc

Access to resources Recommend Favorite